Impact of apolipoprotein Ε4 (APOE ε4) on neuroimaging outcomes in cognitively healthy midlife adults: A systematic review
Abstract
Background: The apolipoprotein E ε4 (APOE ε4) allele is the strongest genetic risk factor for Alzheimer's disease (AD); however, its neurobiological impact assessed by neuroimaging outcomes during midlife, before the onset of cognitive impairment, has not been summarised. This systematic review synthesises evidence on neuroimaging differences associated with APOE ε4-carrier status in cognitively healthy midlife adults and evaluates whether AD-related risk can be detected across imaging modalities.
Methods: A literature search was conducted up until November 2025 to identify studies reporting neuroimaging outcomes in healthy adults aged 30-60 years with known APOE genotype. Eligible studies employed positron emission tomography (PET) and/or magnetic resonance imaging (MRI) and reported outcomes stratified by APOE ε4-carrier status. Risk of bias was assessed using the ROBINS-E tool, and a narrative synthesis was performed.
Results: Searches yielded 7786 articles, and 46 studies met the inclusion criteria. Nine studies used PET, forty used MRI, and three of these studies employed both modalities. Substantial heterogeneity in methods and outcome reporting meant that a meta-analysis was not feasible. PET evidence consistently identified greater amyloid deposition and lower glucose metabolism in midlife APOE ε4-carriers compared with non-carriers, while MRI findings most reliably indicate higher cerebral blood flow. In contrast, other MRI-derived structural, microstructural,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Learning from First-Generation Qualitative Approaches in the IS Discipline: An Evolutionary View and Some Implications for Authors and Evaluators (PART 1/2)
- Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
- Prosthesis: New Technological Opportunities and Innovative Biomedical Devices
- The history and future of neural modeling for cochlear implants
- Ryanodine receptors: waking up from refractoriness
- Novel Transgenic Rabbit Model Sheds Light on the Puzzling Role of Matrix Metalloproteinase-12 in Atherosclerosis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.